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Abstract 
 
Background: Dexamethasone intravitreal implant (DEX) largely showed his safety and efficacy for the treatment of cases of 
macular edema. Even if uncommon, delivery dislocation in anterior chamber has been described in Literaure as complication of the 
injection procedure, leading to irreversible endothelial cell loss in the majority of cases.  
We report a case of a 66-year-old man with pain and vision loss in his left eye. The anamnesis revealed a recent intravitreal 
injection of DEX implant for a persistent cystoid macular edema related to central retinal vein occlusion. Anterior segment 
examination showed corneal edema and the rod implant adherent to corneal endothelium. A large peripheral iridectomy was 
evident with retroillumination and IOL appeared good centered in the bag. The implant was removed but corneal decompensation 
was irreversible. One month later, an endothelial keratoplasty was successfully performed restoring corneal transparency. 
DEX intravitreal implant can migrate from vitreous cavity to anterior chamber and lead to irreversible corneal decompensation by 
mechanical and chemical toxicity on corneal endothelium. Removeal of the implant is necessary to avoid total endothelial 
decompensation. Despite this, in some cases endothelial keratoplasty had to be performed. 
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Case report 
 
   Ozurdex® (Allergan Inc., Irvine, CA, USA) is a 
biodegradable intravitreal slow release delivery largely 
used for the management of macular edema due various 
pathological conditions such diabetes [1] retinal vein 
trombosis [2] Irvine-Gass syndrome [3] and 
noninfectious uveitis [4]. Anterior chamber dislocation of 
DEX implant was described as rare complication of the 
intravitreal injection [5]. 
 
 
 
 
   Several cases had to be managed by surgical removal of 
the implant in presence of corneal endothelial 
decompensation or anterior complications [6]. 
However, repositioning of the implant into the vitreal 
cavity was described as efficient and safe procedure when 
anterior chamber migration does not generate corneal 
decompensation [7]. 
   In this paper, we describe the case of a Descemet 
stripping endothelial keratoplasty in a patient who 
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suffered of corneal endothelial decompensation leaded by 
antherior chamber migration of an intravitreal Ozurdex 
implant. 
   A 66-year-old man with a history of recent 
dexamethasone intravitreal implant injection presented 
with pain and progressive loss of vision in his left eye. 
The patient reported previous diagnosis of cystoid 
macular oedema  due to central retinal vein occlusion 
(CRVO) refractory to anti-VEGF therapy in his left eye. 
For this reason he was scheduled for DEX intravitreal 
injection in the left eye. He also reported 
phacoemulsification with intraocular lens implantation in 
both eyes two years before the diagnosis of CRVO. 
Slit lamp examination of his left eye showed marked 
pericheratic injection, total corneal decompensation and 
the steroid implant adherent to corneal endothelium 
(Figure 1). 
 
 
Figure 1. Ozurdex dislocated in anterior chamber 
 
 
 
   Although the rear structures were poorly evaluated, a 
large peripheral iridectomy was evident with 
retroillumination and IOL appeared in position. 
Best spectacle corrected visual acuity (BSCVA) was hand 
motion. Intraocular pressure (IOP) was 28 mmHg.  
   Because of the incipient corneal decompensation and 
the high intraocular pressure, he was scheduled for 
removal of the implant from the anterior chamber, after 
administration of 500 cc of mannitol to 18% in solution, 
in order to lower the IOP. 
   The removing was performed using the same procedure 
described by Stelton et al. [8]. 
Topical 5% hypertonic salted solution and 0.2% 
Betamethasone associated with 0.5% Chloramphenicol 
eyedrops was administred 4 times a day for one month. 
   One month after surgery, BSCVA was hand motion 
and slint lamp biomicroscopy showed the persistence of 
corneal oedema, leaded by the irreversible endothelial cell  
loss caused by the dislocated implant. Endothelial cell 
count was 450 cell/mm2. 
   In view of this scenario, we decided to perform 
Descemet stripping endothelial keratoplasty (DSEK)  to 
restore corneal transparency. 
DSEK was performed through a 4 mm temporal corneal 
incision. An anterior chamber cannula was inserted for 
paracentesis. Descemet membrane of the recipient was 
stripped under air infusion from the posterior corneal 
stroma over a region corresponding to the dimensions of 
the graft. The existing peripheral iridectomy helped to 
avoid postoperative pupillary block. The graft was 
inserted into the eye through the 4 mm corneal incision 
using a Busin glide (Asico, Westmont, IL). Then, the 
corneal incision was closed with 2 to 3 interrupted 10-0 
nylon sutures and a complete air filling was performed.      
   Fluid that accumulated between the recipient’s stroma 
and the graft was drained through small incisions made 
in the midperipheral cornea of the recipient. Following 
the procedure, the patient received a systemic dose of 4 
mg betamethasone and topical application of 0.3% 
gatifloxacin and 0.1% betamethasone eyedrops 4 times 
daily, tapering the drops during 3 months. 
   At 1 month follow up, BSCVA was 0.53 logMar. 
Corneal edema was almost completely resolved and 
corneal endothelial cell count was 2100 cell/mm2  
(Figure 2). 
 
 
Figure 2. One month after DSEK 
 
 
Discussion 
 
   DEX intravitreal implant can migrate from vitreous 
cavity to anterior chamber. 
Prior vitrectomy, disrupted posterior capsule, previous 
iridectomy, aphakic lens status, face down position are 
known risk factors for the anterior chamber migration 
[9], [10]. 
   Corneal decompensation is the most important 
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complication which can occur in this case.      
   Dexamethasone rod resulted toxic for corneal 
endothelium with two possible mechanisms. First, the 
mechanical trauma due to the rod, especially during the 
first month, when the implant is more rigid [11]. 
   Secondly, a chemical toxicity as from DEX , which 
induces both apoptosis and necrosis to corneal 
endothelial cells, as other components of the implant 
(lactic acid or glycolic acid) [12]. 
Surgery is necessary in the majority of cases for successful 
removing the implant, but often corneal edema resulted 
irreversible. 
   In this cases, endotelial keratoplasty have to be 
performed to restore corneal transparency and to obtain a 
visual recovery. 
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